Who Owns Ocrevus?

Ocrevus operates within Roche's corporate responsibility programs, focusing on environmental impact of biologic pharmaceuticals, manufacturing sustainability, and ethical clinical development.

Environmental Risk Assessment: Roche has conducted comprehensive environmental risk assessments for ocrelizumab, examining its behavior in environmental systems and potential ecological impacts. The assessment evaluates the biologic's persistence in water systems and potential effects on aquatic ecosystems, following regulatory requirements for pharmaceutical environmental impact assessment.

Manufacturing Sustainability: Ocrevus is manufactured at Roche's biotechnology facilities in the United States, Switzerland, and Germany. Roche reported that sustainable electricity comprised 86.2% of total electricity usage in 2024. The company has committed to reducing total environmental impact by half between 2019 and 2029, with Ocrevus manufacturing contributing through energy-efficient biologic production processes.

Clinical Trial Ethics: Ocrevus was developed through clinical trials that included diverse patient populations and addressed the significant unmet medical need in primary progressive multiple sclerosis. The development program followed Good Clinical Practice guidelines. The development of Ocrevus for PPMS represented an important advancement in addressing a patient population with no prior treatment options.

Patient Access: Roche has implemented patient access programs for Ocrevus to address the high cost of biologic therapies, including financial assistance, insurance navigation support, and distribution logistics.

2025 Breakthrough Prize in Life Sciences: Stephen Hauser, a key researcher involved in ocrelizumab development, received the 2025 Breakthrough Prize in Life Sciences for his role in redefining multiple sclerosis treatment. The Breakthrough Prize is one of the most prestigious scientific awards, recognizing researchers who have made major breakthroughs in their fields.

FDA Breakthrough Therapy Designation: Ocrevus received FDA Breakthrough Therapy Designation for primary progressive multiple sclerosis, recognizing the drug's potential to address a serious condition with significant unmet medical need.

First Treatment for PPMS: The FDA approval of Ocrevus in 2017 as the first treatment for both relapsing and primary progressive MS was recognized as a major regulatory milestone in neurological drug development.

Bestselling MS Drug: Ocrevus has become the bestselling drug in the history of multiple sclerosis treatment, with 2025 sales of CHF 7.0 billion making it Roche's highest-selling pharmaceutical product.

Subcutaneous Formulation Innovation: The 2024 FDA approval of Ocrevus Zunovo, the first and only twice-a-year 10-minute subcutaneous injection for MS, received recognition for improving patient convenience and treatment administration.

Fenebrutinib Phase III Results (November 2025): Roche's announcement of positive Phase III results for fenebrutinib in both RMS and PPMS was recognized as a significant milestone in MS drug development, with the potential to deliver the first oral high-efficacy treatment for both forms of MS.

Progressive Multifocal Leukoencephalopathy (PML) Risk: The most significant safety concern associated with Ocrevus is the risk of PML, a rare but often fatal brain infection caused by the JC virus. While no PML cases were observed in Ocrevus clinical trials, postmarketing surveillance has identified PML cases in patients treated with ocrelizumab. As of December 2024, 10 cases of PML had been reported in people receiving Ocrevus treatment since FDA approval. This risk led Genentech to add PML warnings to the Ocrevus prescribing label and implement enhanced monitoring protocols.

Postmarketing Safety Surveillance: The emergence of PML cases in real-world use, despite their absence in clinical trials, has raised questions about the adequacy of clinical trial safety monitoring for rare adverse events and the importance of postmarketing surveillance for biologic therapies.

Risk-Benefit Assessment Debate: The PML risk has created ongoing debate about the risk-benefit profile of Ocrevus, particularly for patients with less aggressive forms of MS. Healthcare professionals and patient advocacy groups have discussed how to balance Ocrevus's clinical benefits against the small but serious risk of PML.

Monitoring and Screening Requirements: The PML risk has necessitated comprehensive monitoring protocols for Ocrevus patients, including regular JC virus testing and MRI surveillance. These monitoring requirements add complexity and cost to treatment.

Comparative Safety Concerns: The PML risk associated with Ocrevus has been compared to similar risks with other B-cell depleting therapies used in MS treatment, influencing treatment selection decisions and discussions about relative safety profiles of different MS disease-modifying therapies.

Regulatory Response: The FDA and other regulatory agencies have responded to PML cases by requiring updated safety information and monitoring protocols for Ocrevus, reflecting the ongoing assessment of Ocrevus's safety profile.